Toevolution

The global compression therapy market size is projected to reach USD 4.51 billion by 2026, exhibiting a CAGR of 5.2% during the forecast period. Rising prevalence of cancer will be a key growth driver for this market in the coming decade, finds Fortune Business Insights™ in its report, titled “Compression Therapy Market Size, Share and Industry Analysis By Product (Compression Garments {Compression Bandages, Compression Stockings, and Others}, Compression Pumps, and Others), By Application (Venous Leg Ulcer, Deep Vein Thrombosis (DVT), Lymphedema, and Others), By End User (Hospitals & Clinics, Nursing Care Centers, Home Care, and Others), and Regional Forecast, 2019-2026”. The global disease burden of cancer, according to the International Agency for Research on Cancer (IARC), rose by an estimated 18.1 million new cases in 2018.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/compression-therapy-market-102689

List of Top Players Covered in the Report:

Tactile Systems Technology, Inc.
Smith & Nephew
medi GmbH & Co. KG
Arjo
SIGVARIS
Bio Compression Systems, Inc.
EssityAktiebolag (publ)
PAUL HARTMANN Pty. Ltd
3M
Cancer therapy, especially for breast and prostate cancers, generally involves dissection of lymph nodes, which causes disruption in the filtering mechanism of the lymphatic system in the body. As a result, lymph fluid accumulates and causes massive swelling of limbs or tissues, a condition known as lymphedema. Worldwide prevalence of this condition, as reported by the National Institutes of Health, is around 250 million. One of the most commonly used treatment options for lymphedema is compression therapy and with increasing incidence of this condition, the demand for these therapies is set to steadily rise.

Regional Analysis

Healthy R&D Funding to Fuel the Market in North America

The market size in North America stood at USD 1.05 billion in 2018 backed by concerted investment in healthcare research and development by the private and public sectors. In addition to that, rising geriatric population and strong presence of global companies is anticipated to aid the region to dominate the compression therapy market share during the forecast period. In Europe, the primary growth propeller will be the development and launch of innovative products by players in the region. On the other hand, steadily increasing number of patients with lymphatic and venous conditions is expected to augur well for the market in Asia-Pacific.

Competitive Landscape

Focused Investment in Innovate to Heat Up Competition

One of the leading compression therapy market trends is the high priority that key companies in this market are giving to R&D and innovation. This intense focus on creating novel solutions for increasingly complex health issues is enabling these players to strengthen their market presence and broaden their range of offerings.

According to the World Bank, approximately 84% populace in Germany depend on Internet and around 75% populace in the U.S. are subscribers of the Internet, which augments the global ePharmacy market growth. Fortune Business Insights states that the global ePharmacy market is projected to reach US$ 177,794.9 Mn by 2026, thereby exhibiting an impressive CAGR of 17.3% during the forecast period (2019-2026). The company further states that the global market was valued at US$ 49,727.7 Mn in 2018. According to a published report by Fortune Business Insights, titled, “ePharmacy: Global Market Analysis, Insights and Forecast, 2019-2026,” the global ePharmacy market will witness notable growth during the forecast period due to the technological advancements based on artificial intelligence.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/epharmacy-market-100238

Fortune Business Insights has profiled some of the prominent market players operating in the global ePharmacy market. They are as follows:

DocMorris
CVS Health Corporation
Express Script Holding Company
Walgreen Co.
Optum Rx, Inc.
Giant Eagle, Inc.
Walmart Stores, Inc.
Rowland Pharmacy
The Kroger Co.
Other players
Increasing Adoption of E-commerce Websites to Favor Growth in Asia Pacific

Geographically, the global ePharmacy market is grouped into Asia Pacific, North America, the Middle East and Africa, Europe, and Latin America. Out of these regions, North America is expected to remain in the leading position in the global ePharmacy market during the forecast period. The growth is attributed to the rapid shift of consumers towards online retailers from offline pharmacies. Also, increasing usage of smartphones and high speed of the Internet are expected to aid North America in gaining the highest global ePharmacy market share in the forthcoming years. Furthermore, a rise in geriatric population, increasing online orders, and growing adoption of online platforms will drive the market growth in this region.

Europe and Asia Pacific, on the other hand, are projected to exhibit significantly high CAGR during the forecast period. In Europe, numerous prominent market players have begun offering products at lucrative rates. This will positively impact growth of ePharmacy market in this region. Asia Pacific, on the other hand, has been witnessing higher adoption of e-commerce websites and increasing patient pool. Moreover, the healthcare infrastructure in this region is on the verge of becoming prosperous. All these factors are anticipated to fuel ePharmacy market growth in Asia Pacific in the coming years.

Key Market Players to Focus on Bagging Funds for Expanding Online Platforms

Several key market players operating in the global ePharmacy market have begun exploring and implementing new strategies to provide the consumers with smooth service. Fortune Business Insights has listed a few key developments that have occurred in the global ePharmacy market since the past few years:

Meds, a Swedish online pharmacy announced in January 2019 that it raised US$ 5.5 million in a funding round conducted by Inbox Capital, a family-owned venture capital company, headquartered in Sweden. The total amount of the startup has increased to US$ 10.5 million. Meds sells healthcare, beauty products, prescription, and non-prescription drugs. They have received permission from the Swedish Medical Product Agency to sell those. According to the company, approximately 40% of the sales come from the households in the Stockholm area as the home delivery service takes less than two hours. After receiving the funds, the company declared that it would soon expand their area of delivery to both Gothenburg and Malmö. Also, the company has planned to expand its warehouse area.

According to the World Bank, approximately 84% populace in Germany depend on Internet and around 75% populace in the U.S. are subscribers of the Internet, which augments the global ePharmacy market growth. Fortune Business Insights states that the global ePharmacy market is projected to reach US$ 177,794.9 Mn by 2026, thereby exhibiting an impressive CAGR of 17.3% during the forecast period (2019-2026). The company further states that the global market was valued at US$ 49,727.7 Mn in 2018. According to a published report by Fortune Business Insights, titled, “ePharmacy: Global Market Analysis, Insights and Forecast, 2019-2026,” the global ePharmacy market will witness notable growth during the forecast period due to the technological advancements based on artificial intelligence.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/epharmacy-market-100238

Fortune Business Insights has profiled some of the prominent market players operating in the global ePharmacy market. They are as follows:

DocMorris
CVS Health Corporation
Express Script Holding Company
Walgreen Co.
Optum Rx, Inc.
Giant Eagle, Inc.
Walmart Stores, Inc.
Rowland Pharmacy
The Kroger Co.
Other players
Increasing Adoption of E-commerce Websites to Favor Growth in Asia Pacific

Geographically, the global ePharmacy market is grouped into Asia Pacific, North America, the Middle East and Africa, Europe, and Latin America. Out of these regions, North America is expected to remain in the leading position in the global ePharmacy market during the forecast period. The growth is attributed to the rapid shift of consumers towards online retailers from offline pharmacies. Also, increasing usage of smartphones and high speed of the Internet are expected to aid North America in gaining the highest global ePharmacy market share in the forthcoming years. Furthermore, a rise in geriatric population, increasing online orders, and growing adoption of online platforms will drive the market growth in this region.

Europe and Asia Pacific, on the other hand, are projected to exhibit significantly high CAGR during the forecast period. In Europe, numerous prominent market players have begun offering products at lucrative rates. This will positively impact growth of ePharmacy market in this region. Asia Pacific, on the other hand, has been witnessing higher adoption of e-commerce websites and increasing patient pool. Moreover, the healthcare infrastructure in this region is on the verge of becoming prosperous. All these factors are anticipated to fuel ePharmacy market growth in Asia Pacific in the coming years.

Key Market Players to Focus on Bagging Funds for Expanding Online Platforms

Several key market players operating in the global ePharmacy market have begun exploring and implementing new strategies to provide the consumers with smooth service. Fortune Business Insights has listed a few key developments that have occurred in the global ePharmacy market since the past few years:

Meds, a Swedish online pharmacy announced in January 2019 that it raised US$ 5.5 million in a funding round conducted by Inbox Capital, a family-owned venture capital company, headquartered in Sweden. The total amount of the startup has increased to US$ 10.5 million. Meds sells healthcare, beauty products, prescription, and non-prescription drugs. They have received permission from the Swedish Medical Product Agency to sell those. According to the company, approximately 40% of the sales come from the households in the Stockholm area as the home delivery service takes less than two hours. After receiving the funds, the company declared that it would soon expand their area of delivery to both Gothenburg and Malmö. Also, the company has planned to expand its warehouse area.

The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights™ published this information in an upcoming report, titled, “Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing Autoimmune Myopathy (NAM), Others), By Treatment (Corticosteroids, Immunosuppressants, Intravenous Immunoglobulins, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026.”

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/idiopathic-inflammatory-myopathy-treatment-market-100198

Fortune Business Insights™ profiles some of the most renowned companies present in the idiopathic inflammatory myopathy treatment market. They are as follows:

Grifols, S.A.
ImmunoForge
Shire (Takeda Pharmaceutical Company Limited)
ORPHAZYME A/S
Mylan N.V.
Biotest AG
Pfizer Inc.
CSL Limited (CSL Behring)
LFB Group
Kedrion S.p.A.
Other key market players
Key Takeaways from the Report

Quick outlook of the market entropy, such as new product launches, collaborations, deals, mergers and acquisitions, and agreements of key players.
Elaborate information about the idiopathic inflammatory myopathy treatment market trends, growth aspect, complication, opportunities, and challenges.
In-depth details of the performance of competitors.
Urgent Need for Modern Therapeutics to Boost Growth

Nowadays, numerous new, modern therapies are emerging across the world. The demand for more effective therapeutics is also rising day by day. Earlier, the traditional treatment options had limitations for the doses of immunosuppressants and glucocorticoids. They could be used up to a certain extent. However, today’s innovative therapeutic options help in treating a wide range of myositis.

Moreover, as more and more difficult-to-treat cases of idiopathic inflammatory myopathy increased, mankind realized the dire need for state-of-the-art therapies. It further created a high unmet demand for treatment options. It is expected to be one of the most crucial idiopathic inflammatory myopathy treatment market growth drivers.

The global hereditary angioedema treatment market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017. The global market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global hereditary angioedema treatment market in various segments and offer a comprehensive overview.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164

some of the key players in the global Hereditary Angioedema Treatment Market:

BIOCRYST PHARMACEUTICALS INC.
Ionis Pharmaceuticals Inc.
Attune Pharmaceuticals
Arrowhead Pharmaceuticals Inc.
Adverum
According to the report, the hereditary angioedema treatment market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025) also. Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute the expansion of the hereditary angioedema treatment market in North America. The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, increasing number of product innovations in the region backed by high presence of hereditary angioedema drugs manufacturers will give tailwinds to growth witnessed by the hereditary angioedema treatment market.

C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period

In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.

Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global hereditary angioedema treatment market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the global market.

Shire, CSL Behring, and Pharming Group NV to Lead the Global Market

The global hereditary angioedema treatment market is witnessing entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global hereditary angioedema treatment market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.

The Global “Pulse Oximeters” Market is likely to grow in the coming years due to increasing usage clearances from the Food and Drug Administration (FDA). According to a report published by Fortune Business Insights, titled “Pulse Oximeters: Global Market Analysis, Insights and Forecast, 2018-2025,” the market is likely to reach US$ 2,657.6 Mn by the end of 2025. Fortune Business Insights states that the market was valued at US$ 1,587.3 Mn in 2017 and will exhibit a CAGR of 6.7% in the forecast period.

Leading Players operating in the Pulse Oximeters Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

Omron Healthcare, Inc.
Philips Benelux
General Electric Manufacturing Company (GEMAC)
Masimo
Messe Düsseldorf GmbH
Vyaire Medical
Opto Circuits India Ltd.
Medtronic
Nonin Medical, Inc
Please visit: https://www.fortunebusinessinsights.com/industry-reports/pulse-oximeters-market-100528

iHealth’s Wristworn Pulse Oximeter to Witness Massive Demand

iHealth’s wrist-worn pulse oximeter’s wide end user coverage can be attributed to its clinical efficacy and most importantly, its ease of use. The device is available on e-commerce websites such as Amazon and the ease of availability for iHealth’s latest device is a leading factor that has contributed to the growth of the global market.

The device can continuously monitor blood oxygen saturation levels along with the pulse rate, both within a short span of time. The device is integrated with a LED display that shows the oxygen saturation readings. The device operated through the emission of infrared light onto the blood vessels of the fingertip. The device has won over many users and the increasing demand has led to the distribution on online retail chains as well as offline stores. iHealth’s latest device is likely to boost the global pulse oximeter market in the forthcoming years.

Market Segmentation:

By Product Type

Fingertip Oximeters
Handheld Oximeters
Tabletop Oximeters
By End User

Hospitals
Ambulatory Surgery Centers and Clinics
Home Healthcare
Others
By Geography

North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Masimo’s Approval for Radius PPG to Trigger Growth

In 2019, Masimo received clearance for its latest pulse oximeter. The ‘Radius PPG’ was approved by the FDA after establishing efficient results through clinical trials. The Radius PPG represents a significant breakthrough in the healthcare industry, particularly for the diagnosis and study of oxygen levels in the blood. The wireless ability allows users to move freely even when they are being examined with the device.

The Telehealth Market is likely to expand considerably with impetus from the ability of telehealth to serve the rural population. According to a report published by Fortune Business Insights, titled “Telehealth: Global Market Analysis, Insights, and Forecast, 2019-2026,” The Global Telehealth Market was valued at US$ 49.8 Bn in 2018. Fortune Business Insights has predicted that the market will reach US$ 266.8 Bn by 2026, thereby exhibiting a CAGR of 23.4%.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/telehealth-market-101065

Key players leading the global Telehealth Market include

American Well
Teladoc Health
Doctor On Demand
GlobalMed
Dictum Health, Inc
LLC
InTouch Technologies, Inc.
MDLIVE Inc.
Encounter Telehealth
HelloMD
SnapMD, Inc.
The ability of Telehealth Market to access and manage healthcare services has led to their rising uptake across the world. Telehealth is used to enhance healthcare services as well as increase feasibility within the healthcare services. Recent technological advancements in telehealth services have created huge potential for growth of the global telehealth market for the forthcoming years.

The ability of telehealth services and products to reach out to rural areas and people who cannot access healthcare facilities has created a huge demand across the world. Resulting from such exceptional benefits for telehealth products, investors have identified this market as a gem and have identified several growth opportunities for the telehealth market companies around the world. Additionally, applications of telehealth in improving coordination and communication among the healthcare team will contribute to the increasing demand for telehealth products across the world.

Company Collaborations Are Proving Chief Growth Drivers

Due to the increasing demand, telehealth market companies are adopting collaborative strategies with the aim of expanding business on a global scale. Furthermore, leading companies in the telehealth industry are focusing on mergers and acquisitions to gain competitive strength. Companies are trying to incorporate modern industrial concepts with a view to gain more end users. Fortune Business Insights expects market collaborations will help companies generate substantial telehealth market revenue.

In April 2018, American Well acquired Avizia Limited with the aim of strengthening its position among the companies in the telehealth industry. American Well’s acquisition of Avizia will help the company take a big leap in the telehealth market, owing to the exceptional portfolio of telehealth services bolstered by Avizia. The report includes company mergers, similar to American Well’s latest acquisition and signifies the impact of such M&As on the global telehealth market.

The Global Diabetes Devices Market is anticipated to exhibit an impressive CAGR of 5.5% on account of rising prevalence of diabetes. Key insights into this fast growing market, valued at US$ 32,441.3 mn in 2018, have been shared by Fortune Business Insights in its report, titled “Diabetes Devices Market Size, Share and Global Trend By Product (Monitoring Devices, Treatment Devices), By Distribution Channel (Institutional Sales, Retail Sales) and Geography Forecast till 2026”. The report brings out the key aspects that will influence the market in the forecast period. Diabetes is a metabolic disease in which the body is unable to process glucose, leading to elevated levels of blood sugar. This happens as the body does not make enough insulin (a hormone made by the pancreas), which helps the glucose enter the cells and supply the body with energy to function. Diabetes devices such as insulin pumps and continuous glucose monitors are used by medical professionals and patients to regulate and monitor blood glucose levels.

Browse Complete Report [email protected]

https://www.fortunebusinessinsights.com/industry-reports/diabetes-devices-market-100803

key industry developments

In September 2018, DiaMonTech GmbH, in, launched a shoebox-sized device that can diagnose the blood glucose levels by using an infrared light beam through the skin.
In February 2019, Tandem Diabetes Care, Inc., received FDA approval for the marketing of the first insulin pump with interoperable technology for children and adults with diabetes. t: Slim X2 insulin pump is the first device to be classified under a new de novo premarket review pathway.
In July 2019, F. Hoffmann-La Roche Ltd. received safety approval for the launch of the Accu-Chek Solo insulin patch pump and wireless touchscreen handheld in Europe.
Top Key Players Covered:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the global Diabetes Devices market. Some of the companies operating the global Diabetes Devices market are;

Hoffmann-La Roche Ltd.
Medtronic
Tandem Diabetes Care, Inc.
BD
Eli Lilly
Company
Sanofi
Increasing Incidence of Diabetes to Fuel the Market

The International Diabetes Foundation has estimated that by 2040, the number of people affected by diabetes will reach 642 million. Diabetes is a lifelong condition and an increasing prevalence of the disease bodes well for the global diabetes devices market. Increasing sedentary lifestyles, lack of exercise, obesity, excessive consumption of fatty and sugar-laced food, and rising stress levels are enhancing the risk of diabetes among people. The market size is expected to expand as novel devices are introduced in the market such as wearable glucose monitoring devices and smart insulin pumps. This expansion will happen on account of rising demand for non-invasive techniques to monitor and regulate blood sugar levels in real-time.

Certain Misgivings May Restrain Market Growth

The global diabetes devices market is expected to grow on the basis of steadily rising adoption rates of various monitoring devices. However, certain devices entail a few risks, which may cast a shadow of doubt in the minds of consumers. For example, insulin pumps are very convenient and efficient way to administer the required amount of insulin into the body. But, there is a fear that patients might get infected at the catheter site. Insulin pumps are also expensive, which can push people to avail traditional methods of diabetes care. Similarly, continuous glucose monitors (CGMs) are known to be inaccurate, especially in case of drop in glucose levels. This is mainly because the technology is still developing. CGMs are also known to be expensive.